NCT00135330 - An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

137

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

exenatide

subcutaneous injection, 5mcg or 10mcg, twice a day

DRUG

rosiglitazone

oral tablet, 2mg or 4mg, twice a day

Trial Locations (19)

Research Site, Phoenix

Research Site, San Francisco

Research Site, Jacksonville

Research Site, Orlando

Research Site, Atlanta

Research Site, Honolulu

Research Site, Indianapolis

Research Site, Boston

Research Site, Pittsfield

Research Site, Minneapolis

Research Site, Rochester

Research Site, Syracuse

Research Site, The Bronx

Research Site, Cincinnati

Research Site, League City

Research Site, New Braunfels

Research Site, San Antonio

Research Site, Renton

Research Site, Spokane